Corona Remedies IPO Allotment Status Analyzed
Corona Remedies’ initial public offering (IPO) was a huge success, attracting a massive amount of investor interest. The company raised ₹655.37 crore, significantly exceeding initial expectations. This strong response indicates confidence in Corona Remedies’ future prospects.
Key Points
- Huge investor interest: IPO subscribed over 137 times, a record.
- Qualified investors drove demand: QIBs subscribed 278.52 times.
- Retail investors showed interest: Subscription rate 28.73 times.
- Allotment expected today: Investors eagerly await the final outcome.
- Check status online: Use BSE, NSE, or Bigshare Services websites.
- Grey market signals: Unlisted shares traded at ₹1357, high GMP.
The IPO received a remarkable response, with investors bidding for 62.65 crore shares, far more than the 45.72 lakh shares initially offered. This overwhelming demand was largely driven by Qualified Institutional Buyers (QIBs) and Non-Institutional Investors (NIIs), both of whom significantly oversubscribed their allotted quotas. The retail investor segment also contributed to the strong response.
Investors can track the allotment status online. The official websites of the BSE, NSE, and Bigshare Services are the primary places to check. These websites provide up-to-date information on the progress of the allotment process.
Furthermore, the grey market activity offers a glimpse into potential listing gains. Unlisted shares of Corona Remedies were trading at ₹1357, indicating a significant grey market premium (GMP) of around 27.78% above the upper price band of ₹1062. This signals strong anticipation for the stock’s listing.
Corona Remedies shares are scheduled to list on the BSE and NSE on Monday, December 15, 2025. However, it’s important to remember that grey market premiums are unofficial and shouldn’t be the only factor considered when investing.
“The strong IPO response reflects investors’ belief in Corona Remedies’ potential for growth and success.”
